Multiple large bowel resections: Potential risk factor for anastomotic leak by E. Kalogera et al.
Gynecologic Oncology 130 (2013) 213–218
Contents lists available at SciVerse ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r .com/ locate /ygynoMultiple large bowel resections:
Potential risk factor for anastomotic leak☆,☆☆
Eleftheria Kalogera a, Sean C. Dowdy a, Andrea Mariani a, Amy L. Weaver b, Giovanni Aletti c,
Jamie N. Bakkum-Gamez a, William A. Cliby a,⁎
a Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, USA
b Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA
c European Institute of Oncology, Milan, Italy
H I G H L I G H T S
• Multiple large bowel resections increased the risk of anastomotic leak (AL) and protective diverting stomas decreased the risk.
• AL patients had longer length of stay and were less likely to start chemotherapy.
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Objectives. Identify risk factors of anastomotic leak (AL) after large bowel resection (LBR) for ovarian
cancer (OC) and compare outcomes between AL and no AL.
Methods. All cases of AL after LBR for OC between 01/01/1994 and 05/20/2011 were identiﬁed and matched
1:2with controls for age (±5 years), sub-stage (IIIA/IIIB; IIIC; IV), anddate of surgery (±4 years). Patient-speciﬁc
and intraoperative risk factors, use of protective stomas, and outcomes were abstracted. A stratiﬁed conditional
logistic regression model was ﬁt to determine the association between each factor and AL.
Results. 42 AL cases were evaluable andmatched with 84 controls. Two-thirds of the AL had stage IIIC disease
and >90% of both cases and controls were cytoreduced to b1 cm residual disease. No patient-speciﬁc risk factors
were associated with AL (pre-operative albumin was not available for most patients). Rectosigmoid resection
coupled with additional LBR was associated with AL (OR = 2.73, 95% CI 1.13–6.59, P = 0.025), and protective
stomas were associated with decreased risk of AL (0% vs. 10.7%, P = 0.024). AL patients had longer length of
stay (P b 0.001), were less likely to start chemotherapy (P = 0.020), and had longer time to chemotherapy
(P = 0.007). Cases tended to have higher 90-day mortality (P = 0.061) and were more likely to have poorer
overall survival (HR = 2.05, 95% CI 1.18–3.57, P = 0.011).
Conclusions.Multiple LBRs appear to be associated with increased risk of AL and protective stomas with de-
creased risk. Since AL after OC cytoreduction signiﬁcantly delays chemotherapy and negatively impacts survival,
surgeons should strongly consider temporary diversion in selected patients (poor nutritional status, multiple
LBRs, previous pelvic radiation, very low anterior resection, steroid use).© 2013 Elsevier Inc. All rights reserved.esection; AL, anastomotic leak;
C, time to chemotherapy; OS,
resection.
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Ovarian cancer (OC) is widely recognized as a systemic disease given
its propensity to disseminate along peritoneal surfaces, frequently in-
volving the bowel and extending to the upper abdomen. Most patients
(up to 70%) will present with advanced stage disease [1,2]. Primary
cytoreductive surgery followed by platinum- and taxane-based chemo-
therapy constitutes current standard treatment [3]. Despite advances in
surgical techniques and systemic chemotherapy over the past 3 decades,
ovarian cancer remains the leading cause of cancer death amongwomen
with gynecologic malignancies [4] with 5-year disease-free survival
rates not exceeding 30% [5].
Table 1
Distribution of stage and residual diseases; A. AL cases vs. controls; B. Stoma vs. no
stoma patients.
A. Cases (n = 42) Controls (n = 84) P-valuea
Stage –
III, IIIA, IIIB 4 (9.5%) 8 (9.5%)
IIIC 27 (64.3%) 54 (64.3%)
IV 11 (26.2%) 22 (26.2%)
Residual diseaseb 0.81
0 cm 14 (33.3%) 28 (34.2%)
0–1 cm 24 (57.2%) 47 (57.3%)
>1 cm 4 (9.5%) 7 (8.5%)
B. Stoma (n = 9) No stoma (n = 75) P-valuec
Stage 0.56
III, IIIA, IIIB 0 (0%) 8 (10.7%)
IIIC 6 (66.7%) 48 (64%)
IV 3 (33.3%) 19 (25.3%)
Residual disease 0.48
0 cm 3 (33.3%) 25 (39.1%)
0–1 cm 6 (66.7%) 32 (50%)
a P-value from a univariate conditional logistic regression model.
b Missing data on residual disease in 2 controls.
c Categorical variables: Chi-square test.
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provement with cytoreduction to microscopic residual disease (RD)
compared to the current deﬁnition of “optimal” cytoreductive surgery
(RD ≤1 cm) [6–10]. In order to achieve maximal cytoreduction,
extensive surgery, including large bowel resection (LBR), may be
required.
A well-recognized complication of LBR is anastomotic leak (AL)
which, although infrequent, can be a catastrophic event associated
with signiﬁcant morbidity, mortality and increased hospital costs.
Rates of AL range from 0.8% to 6.8% in the gynecologic oncology liter-
ature [11–15]. In colorectal literature, published mortality rates asso-
ciated with AL range from 6% to 22% [16–21]. Historically, AL was
thought to only impact 30-day mortality and not long-term colon
cancer survival [22,23], however, more contemporary studies indicate
that an AL portends a signiﬁcant reduction in long-term survival as
well [24–28]. Although the impact of AL in the long-term survival of
OC patients has not been previously studied, the consequences of AL
and the resultant delay in chemotherapy in a cancer where approxi-
mately 95% of patients will require adjuvant chemotherapy may be
substantially more detrimental than in colorectal cancer patients.
Patient-speciﬁc and intraoperative factors have been shown to inde-
pendently predict AL after LBR in colon cancer patients and include
poor nutritional status (preoperative albumin b3.0 g/dL), compromised
physical status (ASA score 3 or 4), alcohol and steroid use, smoking, obe-
sity, prior bevacizumab receipt, previous pelvic irradiation, operative
time more than 2 h, intra-operative septic conditions, peri-operative
blood transfusion, and most importantly, distance of anastomosis from
the anal verge [17,29–38]. The limited number of studies in the OC
patient population have shown that previous pelvic irradiation, poor nu-
tritional status and distance of anastomosis from the anal verge are all
important factors, with a very low anastomosis being the most repro-
ducible and signiﬁcant risk factor [14,15,39–42].
In comparison to colorectal literature, there is a relative paucity of
data examining risk factors and short- and long-term outcomes of AL
in OC. Given the profound impact that AL carries in OC patients addi-
tional information to guide peri-operative decision making on divert-
ing stomas is needed. We thus sought to identify factors contributing
to AL after LBR during cytoreductive surgery. Secondarily we aimed to
compare short- and long-term outcomes between OC patients who
suffered a post-cytoreduction AL and matched control patients with-
out AL.
Methods
After obtaining approval by the Institutional Review Board of
Mayo Foundation, all patients who underwent LBR with primary
anastomosis during cytoreductive surgery for primary or recurrent
OC (including fallopian tube and primary peritoneal cancer, collec-
tively referred to as OC for this study) between January 1, 1994 and
May 20, 2011 at the Mayo Clinic were identiﬁed. Medical records
including operative reports were reviewed by the authors and all
cases of AL were identiﬁed. We deﬁned AL as follows: 1) feculent
ﬂuid from drains, wound, or vagina, 2) deﬁnitive radiographic
evidence of extravasation at the anastomotic site, or 3) AL found at
reoperation. Cases of isolated pelvic abscesses near the anastomotic
site with no proven communication with the bowel lumen were not
included. AL cases were matched 1:2 with cases of LBR for OC without
AL (controls) on date of birth (±5 years), stage (IIIA/IIIB; IIIC; IV),
and date of surgery (±4 years).
Patient-speciﬁc risk factors (including age, body mass index (BMI),
ASA score, diabetes mellitus, use of tobacco, preoperative albumin, pre-
operative hemoglobin, history of abdominal and/or pelvic surgery),
intraoperative risk factors (including type of LBR (rectosigmoid
resection (RSR) alone, RSR coupled with an additional LBR, isolated
non-pelvic LBR), perioperative RBC transfusion, end-operative body
temperature, operative time), creation of diverting protective stomasat initial surgery, and outcomes (including hospital length of stay
(LOS), ability to start chemotherapy, time to chemotherapy (TTC),
30- and 90-day mortality, overall survival (OS)) were abstracted.
Patients were followed until death or last follow-up. Patients were
considered positive for tobacco use if they were smokers at time of
surgery or if they had quit less than 10 years prior to surgery. Contin-
uous variables were dichotomized as follows: BMI ≥ 35 kg/m2
(WHO classes II and III obesity), ASA ≥ 3, preoperative albumin
b3.0 g/dL, preoperative hemoglobin b10 g/dL and end-operative
body temperature ≤36 °C.
The distribution of each factor was summarized using standard de-
scriptive statistics, separately for the cases and controls. For each factor
of interest, a separate stratiﬁed conditional logistic regression model
was ﬁt to evaluate the association between the factor and case/control
status, thereby taking into account the matching between the cases
and controls. The functional form of BMI, end-operative body tempera-
ture, and operative time were ﬁrst evaluated using smoothing splines.
Each was identiﬁed as having a linear relationship with the probability
of being a case and was therefore analyzed as a continuous measure. A
stratiﬁed Cox proportional hazards regressionmodel was ﬁt to compare
OS between AL cases and controls. Statistical analysis to compare OC pa-
tients with LBR with protective stoma vs. patients with LBR with no
stoma included Chi-square test for categorical variables and Wilcoxon
rank sum test for continuous variable. OS between stoma and no
stoma patients was compared using the Wilcoxon test. All calculated
P-values were two-sided and P-values less than 0.05 were considered
statistically signiﬁcant. Statistical analyses were performed using the
SAS version 9.2 software package (SAS Institute, Inc., Cary, NC).
Results
There were 43 cases of AL among the 725 cases of LBR with prima-
ry anastomosis performed during the study period. Among the 43 AL
cases, 42 were included in our study cohort and matched 1:2 with
controls. The single case of excluded AL had no matched controls
due to unique factors (age, stage, era of surgery). Distribution of
stage and RD in cases vs. controls is summarized in Table 1A. Over
90% of the AL cases had stage IIIC or IV disease. More than 90% of
both cases and controls were debulked to ≤1 cm RD, with 33.3%
of the cases and 34.2% of the controls having no gross RD. Speciﬁc
data on RD were not available in 2 controls. Among those who
had an AL, 54.8% underwent RSR alone (vs. 70.2% of controls),
38.1% underwent RSR coupled with an additional LBR (vs. 19.1% of
Table 3
Intraoperative variables.
Factor Cases (n = 42) Controls (n = 84) P-valuea
RSR + additional LBR 16 (38.1%) 16 (19.1%) 0.025
OR = 2.73, 95% CI 1.13–6.59
Protective stomas 0 (0%) 9 (10.7%) 0.024
PRBC 35 (83.3%) 72 (85.7%) 0.72
End-operative BTb ≤36 °C 21 (50%) 46 (54.8%) 0.63
OTb in min (mean, SD) 280 (88) 293 (109) 0.43
a P-value from stratiﬁed conditional logistic regression models.
b Body temperature (BT); operative time (OT).
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controls). The technique of anastomosis in AL cases was equally divided
(21/42) between stapled (end-to-end) and hand-sewn; the stapled
techniquewas slightlymore common in controls (51/84, 62.2%). Details
regarding the diagnosis and management of the AL cases can be found
in a previously published manuscript [43]. In brief, the vast majority
of AL underwent reoperation (37/42, 88.1%): 23 patients received a
diverting stoma (loop ileostomy, n = 13; loop colostomy, n = 10),
12 received an end colostomy, one patient underwent excision and
repair of primary anastomosis, and one patient was treated with place-
ment of a deep drain in the pelvis as a deﬁnitive site of AL was not pos-
sible to be identiﬁed intraoperatively. The remaining 5 (11.9%) patients
were treated conservativelywith broad-spectrumantibiotics and drain-
age (CT drainage/drain left in place, n = 4; deep drain from surgery,
n = 1).
Patient-speciﬁc risk factors appear in Table 2. Preoperative albu-
min was not routinely measured during all eras of study which
resulted in approximately half the case and control missing values
such that we were not able to use this factor in subsequent analyses.
There were no signiﬁcant differences in evaluable patient factors be-
tween cases and controls (Table 2). In the case–control analysis of the
intraoperative variables (Table 3), we observed that a signiﬁcantly
higher proportion of AL cases had RSR coupled with additional LBR
compared to controls (38.1% vs. 19.1%, P = 0.025). Multiple LBRs
were thus associated with increased odds of AL; in fact, the odds of
AL was 2.73 times greater in patients with multiple LBRs compared
to patients with RSR only or other non-pelvic LBR (P = 0.025). Surgi-
cal details on the type of LBR of the patients with multiple LBRs are
depicted in Table 4. Perhaps not surprisingly we observed that 9 out
of 84 (11%) controls had undergone prophylactic diverting stomas
(loop ileostomy, n = 6; loop colostomy, n = 3), while no cases of
AL had protective stomas, thus protective stomas were signiﬁcantly
associated with decreased risk of AL (P = 0.024). Of the 9 patients
who received prophylactic diverting stomas, 5 patients underwent a
second reoperation to restore bowel continuity (reversal rate 55.6%;
time to reversal in days: 174, 211, 213, 436, no data). The reasons
for non-reversal were: 1. Interval death within 90 days after surgery
(n = 1); 2. Recurrence of disease before stoma takedown (n = 2);
and 3. No follow-up data available (n = 1). Notably, 50% of cases
and 54.8% of controls experienced an end-operating body tempera-
ture of ≤36 °C. While this factor was not different between cases
and controls, the rate of hypothermia is substantial and may be a
modiﬁable risk factor for overall surgical complications [44].
Not surprisingly, AL cases had longer LOS (P b 0.001), were less
likely to start chemotherapy (P = 0.020), less likely to start chemo-
therapy within 30 days after surgery (P = 0.027), and had longer
TTC (P = 0.007) than controls (Table 5A). Cases tended to have
higher 90-day mortality (P = 0.061) and were signiﬁcantly more
likely to have poorer OS (HR = 2.05, 95% CI 1.18–3.57, P = 0.011)
(Fig. 1): fully 30% of AL cases were not able to start chemotherapy.
Given that protective stomas are thought to prevent devastating
complications of AL, but can in and of itself contributes to complications,Table 2
Patient-speciﬁc variables.
Factor Cases (n = 42) Controls (n = 84) P-valuea
Age (mean, SD) 63.9 (12.3) 64 (11.6) –
BMI ≥ 35 kg/m2 7 (16.7%) 13/81 (16%) 0.86
ASA ≥ 3 24 (57.1%) 40 (47.6%) 0.28
Diabetes mellitus 4 (9.5%) 6 (7.1%) 0.66
Current use of tobacco 4/40 (10%) 8/80 (10%) 0.92
Preop albumin b3.0 g/dL 2/21 (9.5%) 4/47 (8.5%) –b
Preop Hgb b10 g/dL 0 (0%) 6/83 (7.2%) 0.18
History abd/pelvic surgery 29 (69%) 48 (57.1%) 0.19
a P-value from stratiﬁed conditional logistic regression models.
b Too many missing data.we examined the control group exclusively to compare the characteris-
tics and outcomes between stoma and no stoma patients. Stage and RD
distribution were comparable between those who had a protective
stoma and those who had not (Table 1B). Those with stomas tended to
be older (mean (SD): 69.5 years (11.7) vs. 63.4 years (11.5), P = 0.13)
and have higher ASA scores (ASA ≥ 3: 7/9 (77.8%) vs. 33/75 (44%),
P = 0.079), but these differences did not reach statistical signiﬁcance;
there were no statistical differences between these groups in the
remaining patient-speciﬁc variables. With regard to intraoperative vari-
ables, there was a trend towards a higher frequency of multiple
LBRs during OC cytoreduction in the stoma vs. no stoma patients (4/9
(44.4%) vs. 12/75 (16%), P = 0.06) but small numbers limited power;
there was no statistically signiﬁcant difference between stoma and no
stoma patients in percentage of patients receiving red blood cell transfu-
sion (7/9 (77.8%) vs. 65/75 (86.7%), P = 0.61), end-operative body tem-
perature ≤36 °C (6/9 (66.7%) vs. 40/75 (53.3%), P = 0.50) or operative
time (mean (SD): 332.7 min (143.4) vs. 288.7 min (103.9), P = 0.68).
We did not observe any statistically or clinically signiﬁcant differences
in the outcomes between stoma and no stoma patients (Table 5B).
Importantly, placing a protective stoma did not impact the time to
chemotherapy initiation (mean TTC 36.5 days vs. 34 days, P = 0.29
respectively) or OS (Fig. 2).
Discussion
Aggressive OC cytoreduction frequently requires extensive pelvic
and abdominal surgery which may include LBR. Despite advances in
surgical techniques, AL continues to be a serious complication after
LBR that adversely impacts postoperative morbidity and mortality,
ICU admissions, hospital stay and healthcare costs. Given the gravity
of AL and the increased risk proﬁle encountered in OC patients (widely
disseminated intra-abdominal disease, presence of ascites, tumor bur-
den, poor nutritional status, marginal physical status) whichmakes ex-
trapolation from colorectal literature less relevant, additional studies
are needed to guide surgeons' decisionmaking at the time of LBR for OC.
We observed that LOS, ability to start chemotherapy, 90-day mor-
tality and OS were negatively affected by AL. One out of 5 AL patients
died within 90 days of primary surgery; this mortality rate is higher
than the reported rate in the colorectal literature which ranges from
7.3% to 16% [26,45,46]. The marginal physical status reﬂected by the
ASA score combined with the extent of the surgery may account for
the higher postoperative mortality in the OC patient population
compared to the colorectal cancer patients.
Unlike independent risk factors for AL in the colorectal literature,
we did not ﬁnd obesity, ASA status, diabetes mellitus, tobacco use,
preoperative anemia, history of abdominal and/or pelvic surgery,
peri-operative PRBC transfusion, intra-operative hypothermia, or
operative time to impact AL in OC. However, we recognize the limita-
tions of relatively small numbers of AL and speciﬁc risk factors in our
population. We were unable to investigate the association between
preoperative nutritional status and risk of AL in this cohort, but we
and others have reported its independent importance [14,15]. Despite
small numbers we did ﬁnd that RSR when combined with additional
LBR was associated with a nearly 3-fold risk of AL. Salani et al. [47]
Table 4
Characteristics of patients with multiple large bowel resections (LBRs): A. Cases; B. Controls.
Type of LBR N Number of anastomoses Site of ALa
A. Cases with multiple LBRs 16
RSRb + L colon (extended resection) 4 1 Descending colorectostomy (n = 3)
Transverse colorectostomy (n = 1)
RSR + L colon (extended resection) + R colon 1 2 Ileoascending colostomy
and descending colorectostomy
RSR + L colon (wedge) + T colon (wedge) + R colon 1 3 + end colostomy T and L colon wedge resection
anastomotic sites
RSR + R colon 10 2 Sigmoidorectostomy (n = 5)
Ileoascending colostomy (n = 2)
Sigmoidorectostomy and
Ileoascending colostomy (n = 2)
Other (transverse colon defect) (n = 1)
B. Controls with multiple LBRs 16
RSR + L colon 4
1 extended resection 3 1 –
2 resections 1 1 + end colostomy –
RSR + L colon (extended resection) + R colon 1 2 –
RSR + L colon + T colon + R colon (subtotal colectomy) 1 1 –
RSR + L colon + T colon (left hemicolectomy) 1 1 –
RSR + R colon 6 2 –
RSR + R colon + T colon 2 –
RSR + right hemicolectomy 1 2 –
RSR + R colectomy + T colectomy 1 3 –
a Anastomotic leak (AL).
b Rectosigmoid resection (RSR).
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ing optimal primary cytoreductive surgery for advanced OC and
observed a signiﬁcantly higher rate of postoperative complications,
including ﬁstulas/anastomotic breakdown, in the patients undergoing
2 vs. 0–1 bowel resections (5.9% of anastomotic breakdown with
2 bowel resections vs. 4.4% with 0–1 bowel resections). However,
they studied only cases of primary cytoreduction for OC and bowel
resections included both large and small bowel; both of these factors
may account for the difference in the magnitude of the association
between multiple LBRs and AL rate differences between the two stud-
ies. This is the ﬁrst time in the literature that multiple LBRs are shown
to increase the risk of AL, and we believe the matched case–control
approach may have helped to analyze this association. Given our ﬁnd-
ings, we suggest that multiple LBR should be added to the previously
validated independent risk factors of AL in patients with gynecologicTable 5
Perioperative outcomes: A. AL cases vs. controls; B. Stoma vs. no stoma patients.
A.
Factor
Cases
(n = 42)
Controls
(n = 84)
P-valuea
LOSb in days (median, range) 19.5 (5–84) 9.5 (4–36) b0.001
Unplanned ICU admission 15 (35.7%) 10 (11.9%) 0.003
OR = 4.79, 95% CI 1.70–13.48
Ability to start chemotherapy 29/41 (70.7%) 69/75 (92%) 0.020
OR = 0.31, 95% CI 0.11–0.83
TTC ≤ 30 days 5/41 (12.2%) 25/72 (34.7%) 0.027
OR = 0.28, 95% CI 0.09–0.87
TTCb (median, range) 47.5 (25–92) 35.0 (14–136) 0.007
30-Day mortality 1 (2.4%) 2 (2.4%) –c
90-Day mortality 8 (19.1%) 6 (7.1%) 0.061
B.
Factor
Stoma
(n = 9)
No stoma
(n = 75)
P-valued
LOSb in days (median, range) 11 (7.3) 9 (6.0) 0.26
Unplanned ICU admission 3 (33.3%) 7 (9.3%) 0.07
Ability to start chemotherapy 8/8 (100%) 61/67 (91%) 1.00
TTCb (median, range) 36.5 (30–54) 34 (14–136) 0.29
30-Day mortality 0 (0%) 2 (2.7%) 1.00
90-Day mortality 1 (11.1%) 5 (6.8%) 0.51
a P-value from stratiﬁed conditional logistic regression models.
b Hospital length of stay (LOS); time to chemotherapy (TTC).
c Too few events to compare.
d Continuous variables: Wilcoxon rank sum test; categorical variables: Chi-square test.malignancies which include prior pelvic irradiation, poor nutritional
status and short distance from anal verge [14,15,39–42].
The decision to perform a diverting stoma at primary surgery re-
mains controversial with regard to the risk–beneﬁt ratio attributed
to the stoma. In the colorectal literature, while some investigators
have shown a signiﬁcant AL risk reduction with protective stomas
[17,45], others have observed no difference in AL when a stoma is uti-
lized [39,41,42,46,48–54]. In a recent Cochrane systematic review and
meta-analysis of colorectal literature, a 67% relative risk reduction of
clinically signiﬁcant AL was observed [55]; however, the authors
cautioned that there were methodological drawbacks with their anal-
yses. Whether the risk of detectable AL after colorectal surgery is
reduced with diverting stoma remains debated; however, there is
widespread consensus that protective stomas prevent the catastroph-
ic consequences of AL and are associated with reductions in morbid-
ity, emergency reoperation rates, ICU admissions and, importantly,
mortality [41,42,49,56–59]. In contrast to the abundance of data
coming from colorectal literature, studies on the utility of protective
stomas in the OC population are few and, as previously discussed,
extrapolation from colorectal literature in OC patients carries less
relevance not only when discussing risk factors but also managementFig. 1. Overall survival: AL cases vs. controls.
Fig. 2. Overall survival: Stoma vs. no stoma patients.
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after an isolated LBR is a less technically challenging procedure than
after a comprehensive cytoreductive operation involving most of
the peritoneal cavity; the morbidity associated with each scenario is
quite different. Furthermore, AL after bowel resection is difﬁcult to
predict: a signiﬁcant portion of the AL occurs in patients without
previously established classic risk factors [14,15,39–42] such as poor
nutrition, prior radiation and very low level of rectal resection. This
underscores the need for more sensitive predictors and careful analy-
sis of the alternative approach of more liberal use of diverting stomas.
In our series, protective stomas were associated with a decreased risk
of AL. Moreover, it is striking that none of the diverted patients
experienced AL. If we were thus to assume that diverting stomas
completely prevented AL, one third of AL cases would have been
prevented had a stoma been done in all OC patients with multiple
LBR (frequency of multiple LBRs in AL cases: 38.1%). Admittedly,
one must weigh the risks and beneﬁts associated with diverting
stomas compared to risks of AL. Collectively, we found that we
would need to perform prophylactic diverting stomas in 6.6 OC pa-
tients with multiple LBR to prevent one case of AL in this subgroup
of patients with multiple LBR (Number Needed to Treat 6.6). Given
the high cost of AL and the profound signiﬁcance in terms of patient
suffering and ability to complete recommended therapy this may be
a reasonable trade-off but certainly one that should be considered
with the patient in the context of other risk factors and goals.
Protective stomas do not come without potential intrinsic risks. In
addition to increasing hospital costs, a second surgery is required for
reversal and both the stoma itself (necrosis, retraction, hernia, elec-
trolyte and ﬂuid losses) as well as the reversal surgery can be associ-
ated with inherent morbidity ranging from 13% to 28%, albeit serious
complications occur less then b5% of the time [60–64]. Moreover, an
intended temporary stoma may become permanent with colorectal
literature rates of non-reversal ranging from 15% to 50% [24,30,65].
Finally, given that stomas have been associated with adverse psycho-
logical effects and decreased patient quality of life, these aspects must
be weighed when evaluating the risk–beneﬁt ratio of stomas for
women undergoing OC debulking [66]. However, given the substan-
tial mortality following AL after OC cytoreduction and the fact that
none of the diverted patients experienced AL, the beneﬁt of a protec-
tive diverting stoma in well-counseled, appropriately selected pa-
tients should be clear. It is thus critical to risk-stratify OC patients
undergoing cytoreductive surgery and seriously consider diverting
stomas after LBR in high risk groups. Similarly the decision to perform
LBR should be reserved for those patients we can achieve low RD or
for palliation.Our study is limited by the fact that it is retrospective. In addition,
we were unable to analyze preoperative albumin as a risk factor of AL
due to the large number of missing data. However, poor nutritional
status is already a well-established independent predictor of AL
[14,15]. Many of the classic risk factors for AL are not present in the
OC population so are not evaluable in most series, but will be
occasionally present and should not be ignored. In addition, this
study did not address the impact of AL in hospital costs compared
to the impact of diverting stomas including takedown; however, a
cost-analysis study is currently in progress to investigate these issues.
In conclusion, RSR when coupled with additional LBR appears to
signiﬁcantly increase the risk of AL. In agreement with the existing
colorectal literature supporting the use of protective stomas after
LBR as a way to mitigate the adverse sequelae following an AL, we
provide evidence that protective stomas reduce and possibly prevent
AL following OC cytoreduction. In addition to previously established
indications for diverting stoma utilization, we suggest considering
placement of a protective stoma when multiple LBRs have been
performed during OC cytoreduction. Further cost-analysis and quality
of life studies evaluating the impact of prophylactic bowel diversion
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